Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma

Recruiting now · Phase 2

Conditions studied: Indolent B-Cell Non-Hodgkin Lymphoma

In brief

This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.

Key facts

Study ID
NCT06461182
Run by
Koo Foundation Sun Yat-Sen Cancer Center
People needed
15
Starts
2024-04-29
Expected to finish
2027-04-01
Last updated by the study team
2024-06-14

Who can join

Age: 20 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.